Chinese General Practice ›› 2023, Vol. 26 ›› Issue (23): 2912-2917.DOI: 10.12114/j.issn.1007-9572.2023.0050
• Drug Safety • Previous Articles Next Articles
Received:
2023-02-01
Revised:
2023-02-20
Published:
2023-08-15
Online:
2023-02-27
Contact:
GUO Ning
通讯作者:
郭宁
作者简介:
基金资助:
Add to citation manager EndNote|Ris|BibTeX
URL: https://www.chinagp.net/EN/10.12114/j.issn.1007-9572.2023.0050
组别 | 例数 | 年龄( | 性别〔n(%)〕 | NYHA心功能分级〔n(%)〕 | 糖尿病史〔n(%)〕 | 使用BB 〔n(%)〕 | 使用MRA 〔n(%)〕 | |||
---|---|---|---|---|---|---|---|---|---|---|
男 | 女 | Ⅱ级 | Ⅲ级 | Ⅳ级 | ||||||
沙库巴曲缬沙坦组 | 71 | 59.4±11.4 | 46(64.8) | 25(35.2) | 30(42.3) | 31(43.7) | 10(14.0) | 14(19.7) | 67(94.4) | 48(67.6) |
达格列净组 | 53 | 57.3±10.5 | 37(69.8) | 16(30.2) | 20(37.7) | 27(50.9) | 6(11.4) | 5(9.4) | 51(96.2) | 38(71.7) |
χ2(t)值 | 1.069a | 0.346 | 0.677 | 2.474 | 0.003 | 0.239 | ||||
P值 | 0.287 | 0.556 | 0.713 | 0.116 | 0.956 | 0.625 |
Table 1 Comparison of general data between the sacubitril/valsartan group and dapagliflozin group
组别 | 例数 | 年龄( | 性别〔n(%)〕 | NYHA心功能分级〔n(%)〕 | 糖尿病史〔n(%)〕 | 使用BB 〔n(%)〕 | 使用MRA 〔n(%)〕 | |||
---|---|---|---|---|---|---|---|---|---|---|
男 | 女 | Ⅱ级 | Ⅲ级 | Ⅳ级 | ||||||
沙库巴曲缬沙坦组 | 71 | 59.4±11.4 | 46(64.8) | 25(35.2) | 30(42.3) | 31(43.7) | 10(14.0) | 14(19.7) | 67(94.4) | 48(67.6) |
达格列净组 | 53 | 57.3±10.5 | 37(69.8) | 16(30.2) | 20(37.7) | 27(50.9) | 6(11.4) | 5(9.4) | 51(96.2) | 38(71.7) |
χ2(t)值 | 1.069a | 0.346 | 0.677 | 2.474 | 0.003 | 0.239 | ||||
P值 | 0.287 | 0.556 | 0.713 | 0.116 | 0.956 | 0.625 |
组别 | 例数 | SBP(mmHg) | DBP(mmHg) | |||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|
治疗前 | 治疗6个月后 | t配对值 | P值 | 治疗前 | 治疗6个月后 | t配对值 | P值 | |||||
沙库巴曲缬沙坦组 | 71 | 104±4 | 92±5 | 22.870 | <0.001 | 70±4 | 62±4 | 13.790 | <0.001 | |||
达格列净组 | 53 | 103±4 | 95±4 | 17.600 | <0.001 | 70±4 | 65±4 | 8.910 | <0.001 | |||
t值 | 1.594 | 3.779 | 0.205 | 3.578 | ||||||||
P值 | 0.114 | <0.001 | 0.838 | <0.001 | ||||||||
组别 | BMI(kg/m2) | NT-proBNP(ng/L) | HbA1c(%) | |||||||||
治疗前 | 治疗6个月后 | t配对值 | P值 | 治疗前 | 治疗6个月后 | t配对值 | P值 | 治疗前 | 治疗6个月后 | t配对值 | P值 | |
沙库巴曲缬沙坦组 | 23.6±2.9 | 23.2±2.7 | 3.310 | 0.001 | 1 782.79±650.70 | 1 105.39±430.78 | 15.361 | <0.001 | 5.80±0.71 | 5.64±0.61 | 6.930 | <0.001 |
达格列净组 | 24.0±2.2 | 22.8±1.7 | 7.190 | <0.001 | 1 866.62±662.07 | 1 088.55±439.82 | 15.101 | <0.001 | 5.83±0.55 | 5.45±0.39 | 11.405 | <0.001 |
t值 | 0.865 | 1.133 | 0.704 | 0.214 | 0.208 | 2.097 | ||||||
P值 | 0.389 | 0.260 | 0.482 | 0.831 | 0.836 | 0.038 | ||||||
组别 | FBG(mmol/L) | eGFR〔mL·min-1·(1.73 m2)-1〕 | 血钾(mmol/L) | |||||||||
治疗前 | 治疗6个月后 | t配对值 | P值 | 治疗前 | 治疗6个月后 | t配对值 | P值 | 治疗前 | 治疗6个月后 | t配对值 | P值 | |
沙库巴曲缬沙坦组 | 5.36±0.85 | 5.17±0.76 | 5.196 | <0.001 | 84.18±16.09 | 80.63±16.05 | 3.162 | 0.002 | 4.31±0.28 | 4.58±0.34 | 5.169 | <0.001 |
达格列净组 | 5.20±0.70 | 4.73±0.54 | 10.615 | <0.001 | 87.12±15.48 | 88.14±15.86 | 0.720 | 0.475 | 4.39±0.29 | 4.51±0.22 | 2.454 | 0.017 |
t值 | 1.146 | 3.754 | 1.023 | 2.592 | 1.475 | 1.446 | ||||||
P值 | 0.254 | <0.001 | 0.308 | 0.011 | 0.143 | 0.151 | ||||||
组别 | LVEF(%) | LVEDD(mm) | LVESD(mm) | |||||||||
治疗前 | 治疗6个月后 | t配对值 | P值 | 治疗前 | 治疗6个月后 | t配对值 | P值 | 治疗前 | 治疗6个月后 | t配对值 | P值 | |
沙库巴曲缬沙坦组 | 35.39±7.23 | 40.87±6.89 | 11.151 | <0.001 | 67.18±8.74 | 62.72±7.73 | 10.236 | <0.001 | 55.87±9.06 | 50.13±8.16 | 11.012 | <0.001 |
达格列净组 | 34.72±6.95 | 40.70±7.40 | 10.280 | <0.001 | 67.77±8.01 | 63.38±7.88 | 9.981 | <0.001 | 56.57±8.63 | 50.30±9.08 | 10.793 | <0.001 |
t值 | 0.525 | 0.136 | 0.385 | 0.466 | 0.430 | 0.113 | ||||||
P值 | 0.601 | 0.892 | 0.701 | 0.642 | 0.668 | 0.911 | ||||||
组别 | LAD(mm) | 6MWT(m) | ||||||||||
治疗前 | 治疗6个月后 | t配对值 | P值 | 治疗前 | 治疗6个月后 | t配对值 | P值 | |||||
沙库巴曲缬沙坦组 | 42.10±2.70 | 39.97±2.48 | 15.004 | <0.001 | 274.68±59.53 | 348.55±58.56 | 18.310 | <0.001 | ||||
达格列净组 | 42.72±2.69 | 39.81±2.71 | 14.131 | <0.001 | 267.04±49.31 | 356.77±55.22 | 17.199 | <0.001 | ||||
t值 | 1.263 | 0.342 | 0.759 | 0.793 | ||||||||
P值 | 0.209 | 0.733 | 0.449 | 0.430 |
Table 2 Comparison of the indicators before and after treatment in the sacubitril/valsartan and dapagliflozin group
组别 | 例数 | SBP(mmHg) | DBP(mmHg) | |||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|
治疗前 | 治疗6个月后 | t配对值 | P值 | 治疗前 | 治疗6个月后 | t配对值 | P值 | |||||
沙库巴曲缬沙坦组 | 71 | 104±4 | 92±5 | 22.870 | <0.001 | 70±4 | 62±4 | 13.790 | <0.001 | |||
达格列净组 | 53 | 103±4 | 95±4 | 17.600 | <0.001 | 70±4 | 65±4 | 8.910 | <0.001 | |||
t值 | 1.594 | 3.779 | 0.205 | 3.578 | ||||||||
P值 | 0.114 | <0.001 | 0.838 | <0.001 | ||||||||
组别 | BMI(kg/m2) | NT-proBNP(ng/L) | HbA1c(%) | |||||||||
治疗前 | 治疗6个月后 | t配对值 | P值 | 治疗前 | 治疗6个月后 | t配对值 | P值 | 治疗前 | 治疗6个月后 | t配对值 | P值 | |
沙库巴曲缬沙坦组 | 23.6±2.9 | 23.2±2.7 | 3.310 | 0.001 | 1 782.79±650.70 | 1 105.39±430.78 | 15.361 | <0.001 | 5.80±0.71 | 5.64±0.61 | 6.930 | <0.001 |
达格列净组 | 24.0±2.2 | 22.8±1.7 | 7.190 | <0.001 | 1 866.62±662.07 | 1 088.55±439.82 | 15.101 | <0.001 | 5.83±0.55 | 5.45±0.39 | 11.405 | <0.001 |
t值 | 0.865 | 1.133 | 0.704 | 0.214 | 0.208 | 2.097 | ||||||
P值 | 0.389 | 0.260 | 0.482 | 0.831 | 0.836 | 0.038 | ||||||
组别 | FBG(mmol/L) | eGFR〔mL·min-1·(1.73 m2)-1〕 | 血钾(mmol/L) | |||||||||
治疗前 | 治疗6个月后 | t配对值 | P值 | 治疗前 | 治疗6个月后 | t配对值 | P值 | 治疗前 | 治疗6个月后 | t配对值 | P值 | |
沙库巴曲缬沙坦组 | 5.36±0.85 | 5.17±0.76 | 5.196 | <0.001 | 84.18±16.09 | 80.63±16.05 | 3.162 | 0.002 | 4.31±0.28 | 4.58±0.34 | 5.169 | <0.001 |
达格列净组 | 5.20±0.70 | 4.73±0.54 | 10.615 | <0.001 | 87.12±15.48 | 88.14±15.86 | 0.720 | 0.475 | 4.39±0.29 | 4.51±0.22 | 2.454 | 0.017 |
t值 | 1.146 | 3.754 | 1.023 | 2.592 | 1.475 | 1.446 | ||||||
P值 | 0.254 | <0.001 | 0.308 | 0.011 | 0.143 | 0.151 | ||||||
组别 | LVEF(%) | LVEDD(mm) | LVESD(mm) | |||||||||
治疗前 | 治疗6个月后 | t配对值 | P值 | 治疗前 | 治疗6个月后 | t配对值 | P值 | 治疗前 | 治疗6个月后 | t配对值 | P值 | |
沙库巴曲缬沙坦组 | 35.39±7.23 | 40.87±6.89 | 11.151 | <0.001 | 67.18±8.74 | 62.72±7.73 | 10.236 | <0.001 | 55.87±9.06 | 50.13±8.16 | 11.012 | <0.001 |
达格列净组 | 34.72±6.95 | 40.70±7.40 | 10.280 | <0.001 | 67.77±8.01 | 63.38±7.88 | 9.981 | <0.001 | 56.57±8.63 | 50.30±9.08 | 10.793 | <0.001 |
t值 | 0.525 | 0.136 | 0.385 | 0.466 | 0.430 | 0.113 | ||||||
P值 | 0.601 | 0.892 | 0.701 | 0.642 | 0.668 | 0.911 | ||||||
组别 | LAD(mm) | 6MWT(m) | ||||||||||
治疗前 | 治疗6个月后 | t配对值 | P值 | 治疗前 | 治疗6个月后 | t配对值 | P值 | |||||
沙库巴曲缬沙坦组 | 42.10±2.70 | 39.97±2.48 | 15.004 | <0.001 | 274.68±59.53 | 348.55±58.56 | 18.310 | <0.001 | ||||
达格列净组 | 42.72±2.69 | 39.81±2.71 | 14.131 | <0.001 | 267.04±49.31 | 356.77±55.22 | 17.199 | <0.001 | ||||
t值 | 1.263 | 0.342 | 0.759 | 0.793 | ||||||||
P值 | 0.209 | 0.733 | 0.449 | 0.430 |
组别 | 例数 | SBP〔M(P25,P75),mmHg〕 | DBP ( | BMI〔M(P25,P75),kg/m2〕 | NT-proBNP 〔M(P25,P75),ng/L〕 | HbA1c 〔M(P25,P75),%〕 | FBG ( |
---|---|---|---|---|---|---|---|
沙库巴曲缬沙坦组 | 71 | -12(-14,-8) | -8±5 | -0.3(-0.8,0) | -597.00(-912.00,-390.00) | -0.20(-0.30,0) | -0.19±0.31 |
达格列净组 | 53 | -8(-10,-6) | -5±4 | -1.0(-1.7,-0.4) | -769.00(-1 010.50,-524.50) | -0.40(-0.50,-0.20) | -0.47±0.32 |
Z(t)值 | 5.217 | 3.070a | 4.410 | 1.690 | 4.493 | 4.832a | |
P值 | <0.001 | 0.003 | <0.001 | 0.091 | <0.001 | <0.001 | |
组别 | eGFR〔M(P25,P75),mL·min-1·(1.73 m2)-1〕 | K〔M(P25,P75),mmol/L〕 | LVEF〔M(P25,P75),%〕 | LVEDD〔M(P25,P75),mm〕 | LVESD〔M(P25,P75),mm〕 | LAD〔M(P25,P75),mm〕 | 6MWT ( |
沙库巴曲缬沙坦组 | -3.04(-10.30,1.11) | 0.25(-0.06,0.47) | 4.00(2.00,9.00) | -4.00(-6.00,-2.00) | -5.00(-7.00,-3.00) | -2.00(-3.00,-1.00) | 73.87±34.00 |
达格列净组 | 0.05(-3.07,6.00) | 0.13(-0.18,0.37) | 5.00(3.00,8.00) | -3.00(-5.50,-2.00) | -5.00(-9.00,-3.00) | -3.00(-3.50,-2.00) | 89.74±37.98 |
Z(t)值 | 2.495 | 1.541 | 0.866 | 0.053 | 0.612 | 2.830 | 2.444a |
P值 | 0.013 | 0.123 | 0.386 | 0.957 | 0.541 | 0.005 | 0.016 |
Table 3 Comparison of the difference of each indicator before and after treatment between the sacubitril/valsartan and dapagliflozin group
组别 | 例数 | SBP〔M(P25,P75),mmHg〕 | DBP ( | BMI〔M(P25,P75),kg/m2〕 | NT-proBNP 〔M(P25,P75),ng/L〕 | HbA1c 〔M(P25,P75),%〕 | FBG ( |
---|---|---|---|---|---|---|---|
沙库巴曲缬沙坦组 | 71 | -12(-14,-8) | -8±5 | -0.3(-0.8,0) | -597.00(-912.00,-390.00) | -0.20(-0.30,0) | -0.19±0.31 |
达格列净组 | 53 | -8(-10,-6) | -5±4 | -1.0(-1.7,-0.4) | -769.00(-1 010.50,-524.50) | -0.40(-0.50,-0.20) | -0.47±0.32 |
Z(t)值 | 5.217 | 3.070a | 4.410 | 1.690 | 4.493 | 4.832a | |
P值 | <0.001 | 0.003 | <0.001 | 0.091 | <0.001 | <0.001 | |
组别 | eGFR〔M(P25,P75),mL·min-1·(1.73 m2)-1〕 | K〔M(P25,P75),mmol/L〕 | LVEF〔M(P25,P75),%〕 | LVEDD〔M(P25,P75),mm〕 | LVESD〔M(P25,P75),mm〕 | LAD〔M(P25,P75),mm〕 | 6MWT ( |
沙库巴曲缬沙坦组 | -3.04(-10.30,1.11) | 0.25(-0.06,0.47) | 4.00(2.00,9.00) | -4.00(-6.00,-2.00) | -5.00(-7.00,-3.00) | -2.00(-3.00,-1.00) | 73.87±34.00 |
达格列净组 | 0.05(-3.07,6.00) | 0.13(-0.18,0.37) | 5.00(3.00,8.00) | -3.00(-5.50,-2.00) | -5.00(-9.00,-3.00) | -3.00(-3.50,-2.00) | 89.74±37.98 |
Z(t)值 | 2.495 | 1.541 | 0.866 | 0.053 | 0.612 | 2.830 | 2.444a |
P值 | 0.013 | 0.123 | 0.386 | 0.957 | 0.541 | 0.005 | 0.016 |
组别 | 例数 | 低血压停药 | 高钾血症停药 | 肾功能不全停药 | 泌尿系感染停药 | 心力衰竭再入院 |
---|---|---|---|---|---|---|
沙库巴曲缬沙坦组 | 71 | 6(8.5) | 3(4.2) | 3(4.2) | 0 | 7(9.9) |
达格列净组 | 53 | 1(1.9) | 0 | 1(1.9) | 1(1.9) | 4(7.5) |
χ2值 | 1.377 | 0.854 | 0.046 | — | 0.201 | |
P值 | 0.241 | 0.355 | 0.829 | 0.427 | 0.654 |
Table 4 Comparison of clinical event incidence between the sacubitril/valsartan group and dapagliflozin group
组别 | 例数 | 低血压停药 | 高钾血症停药 | 肾功能不全停药 | 泌尿系感染停药 | 心力衰竭再入院 |
---|---|---|---|---|---|---|
沙库巴曲缬沙坦组 | 71 | 6(8.5) | 3(4.2) | 3(4.2) | 0 | 7(9.9) |
达格列净组 | 53 | 1(1.9) | 0 | 1(1.9) | 1(1.9) | 4(7.5) |
χ2值 | 1.377 | 0.854 | 0.046 | — | 0.201 | |
P值 | 0.241 | 0.355 | 0.829 | 0.427 | 0.654 |
[1] |
|
[2] |
中华医学会心血管病学分会,中华心血管病杂志编辑委员会. 中国心力衰竭诊断和治疗指南2014[J]. 中华心血管病杂志,2014,42(2):98-122. DOI:10.3760/cma.j.issn.0253-3758.2014.02.004.
|
[3] |
|
[4] |
|
[5] |
中华医学会心血管病学分会,中国心肌炎心肌病协作组. 中国扩张型心肌病诊断和治疗指南[J]. 临床心血管病杂志,2018,34(5):421-434. DOI:10.13201/j.issn.1001-1439.2018.05.001.
|
[6] |
|
[7] |
|
[8] |
|
[9] |
|
[10] |
|
[11] |
|
[12] |
|
[13] |
|
[14] |
|
[15] |
|
[16] |
李文邦,刘希金,刘佳月,等. 沙库巴曲缬沙坦对慢性心力衰竭患者运动耐量的影响[J]. 临床内科杂志,2022,39(6):392-395. DOI:10.3969/j.issn.1001-9057.2022.06.010.
|
[17] |
王小婕,李学善,任红燕,等. 沙库巴曲缬沙坦治疗老年慢性心力衰竭的效果观察[J]. 宁夏医学杂志,2022,44(4):345-347. DOI:10.13621/j.1001-5949.2022.04.0345.
|
[18] |
柴俊兵,吕钢,刘华,等. 达格列净治疗射血分数降低心力衰竭的临床效果观察[J]. 中华保健医学杂志,2022,24(5):373-375. DOI:10.3969/j.issn.1674-3245.2022.05.005.
|
[19] |
石玉伍,徐通达,李东野. 沙库巴曲缬沙坦钠对射血分数减低型心力衰竭患者肾功能、血压及血清电解质的影响[J]. 中国循证心血管医学杂志,2022,14(1):94-97.
|
[20] |
|
[21] |
|
[22] |
|
[23] |
田得宽,苏晓灵,李卫,等. 沙库巴曲缬沙坦钠对青海地区射血分数降低的心力衰竭患者心功能及心肌纤维化指标的疗效评价[J]. 临床心血管病杂志,2022,38(2):137-141. DOI:10.13201/j.issn.1001-1439.2022.02.011.
|
[24] |
陈姣,周杰,汤冰倩,等. 达格列净治疗糖尿病合并心衰的疗效及其血管内皮功能和炎症因子的影响[J]. 心血管康复医学杂志,2020,29(5):599-603. DOI:10.3969/j.issn.1008-0074.2020.05.18.
|
[25] |
孙敏,张冬颖. 钠-葡萄糖共转运蛋白2抑制剂对2型糖尿病患者心血管保护作用的研究进展[J]. 上海交通大学学报(医学版),2021,41(3):391-395. DOI:10.3969/j.issn.1674-8115.2021.03.019.
|
[26] |
|
[27] |
沈祎玲,祁春梅. 达格列净联合美托洛尔治疗2型糖尿病合并慢性心力衰竭的临床效果[J]. 中国医药,2022,17(12):1804-1808. DOI:10.3760/j.issn.1673-4777.2022.12.010.
|
[1] | WANG Minghang, HAN Weihong, BI Lichan, YANG Jiang, LI Jiansheng. Evaluation Study of Traditional Chinese Medicine Syndrome Differentiation Therapy on the Quality of Life and Efficacy Satisfaction in Elderly Community-acquired Pneumonia Patients after Discharge [J]. Chinese General Practice, 2024, 27(08): 1001-1007. |
[2] | FENG Zhengwen, CHEN Xiaolei, LI Hui, ZHU Chenli, SHAO Shuang, DU Juan. Preliminary Development of Self-assessment Scale for the Ability of Outpatients with Chronic Diseases to Participate in Medication Safety Based on the Delphi Method [J]. Chinese General Practice, 2024, 27(05): 604-611. |
[3] | ZHANG Dongli, SHEN Chong, ZHANG Weichuan, CHEN Haibin, ZHAO Jianjun. Efficacy and Safety of Programmed Death-1/Programmed Death-1 Ligand Inhibitors in the Treatment of Renal Cell Cancer: a Meta-analysis [J]. Chinese General Practice, 2023, 26(30): 3815-3822. |
[4] | LIU Ruifang, XU Fangxing, LIU Tongku, ZHOU Yujie, WU Xiaofan. Evaluation of the Efficacy and Safety of "Crowbar Effect" Technique to Facilitate Balloon Crossing Resistant Chronic Total Occlusions Lesions [J]. Chinese General Practice, 2023, 26(29): 3683-3688. |
[5] | HUANG Dan, ZHANG Qihan, SONG Ge, WANG Qing, LI Yu, JI Xunming, WANG Yuan. Efficacy and Safety of Intermittent Hypoxic Training in the Prevention of Acute Hypoxic Injury [J]. Chinese General Practice, 2023, 26(29): 3640-3644. |
[6] | LIU Minghao, WANG Pan, GAO Lijian, XU Shuqing, WANG Huanhuan, ZHAO Guangxian, CHEN Jue, QIAO Shubin, XU Bo, YUAN Jinqing. Feasibility, Safety and Timing of Secondary Percutaneous Coronary Intervention via Distal Transradial Artery Approach [J]. Chinese General Practice, 2023, 26(27): 3366-3372. |
[7] | LU Bin, XIANG Chong, YUAN Xuesong, CAI Gaojun, WEI Wenfeng, YAN Yongmin. Effectiveness, Safety and Satisfaction of Distal Transradial Artery Approach in Cerebral Angiography [J]. Chinese General Practice, 2023, 26(27): 3378-3382. |
[8] | CHEN Lulu, ZHANG Liping, LI Jingwen, DONG Wenjie, WU Xin'ai. Clinical Effect and Safety of PD-1 Inhibitors plus Fruquintinib as Later-line Treatment for Metastatic Colorectal Cancer [J]. Chinese General Practice, 2023, 26(18): 2262-2267. |
[9] | ZHANG Kang, JI Wenshuai, KONG Xinxin, DU Chen, XIE Kai, WANG Haifeng. Predictive Efficacies of SOFA Score, CURB-65 Score and PSI Score for 28-day Mortality in Patients with Severe Pneumonia: a Comparative Study [J]. Chinese General Practice, 2023, 26(18): 2217-2222. |
[10] | ZHANG Lina, WANG Yan, ZHANG Kanghuai, LI Youjia. Clinical Research Progress of Tirzepatide: a New Hypoglycemic Agent [J]. Chinese General Practice, 2023, 26(15): 1902-1908. |
[11] | WANG Lingxiao, DONG Rongna, ZHOU Bing, GUO Lina, LI Jing. Analysis of the Effect of Human-computer Interaction Intelligent Management on Blood Glucose Control in New-onset Type 2 Diabetes Mellitus Patients [J]. Chinese General Practice, 2023, 26(15): 1817-1823. |
[12] | CHEN Ruimin, LIU Fang, TAN Hong, HAN Shufang, CHEN Yingjian, SU Congcong. Effects of Dapagliflozin on the Expression of MicroRNA-423-5p and Cardiac Function in Patients with Type 2 Diabetes Mellitus and Chronic Heart Failure [J]. Chinese General Practice, 2023, 26(14): 1733-1738. |
[13] | LI Jiaqing, YANG Qing, YUAN Dunlu, HUANG Jingjing, CHANG Qing, NIE Jingwen, ZHOU Zhu, LI Qing. Effectiveness and Safety of Roxadustat for Renal Anemia in Dialysis-dependent Chronic Kidney Disease: a Meta-analysis [J]. Chinese General Practice, 2023, 26(06): 704-710. |
[14] | SONG Pingan, CHEN Xiaoliang, YAO Yuan, GAO Jin, YANG Yang, CUI Hongchun, ZHANG Yi. Efficacy and Safety of PD-1 Inhibitors Monotherapy for Elderly Patients with Advanced Non-small Cell Lung Cancer [J]. Chinese General Practice, 2023, 26(02): 241-247. |
[15] | WU Yining, WAN Ying, HU Chaoyue, SUN Yanan, YU Changhe. A Comparative Study of Outcomes and Measurements Used in Randomized Controlled Trials for Low Back Pain Treated by Western Medicine and Traditional Chinese Medicine [J]. Chinese General Practice, 2022, 25(35): 4433-4442. |
Viewed | ||||||
Full text |
|
|||||
Abstract |
|
|||||